Top

Published in:

01-06-2010

Effect of Liver Steatosis on Therapeutic Response in Chronic Hepatitis C Virus Genotype 1 Infected Patients in Hungary

Authors: Klara Werling, Zsuzsa Schaff, Elek Dinya, Zsolt Tulassay

Published in: Pathology & Oncology Research | Issue 2/2010

Abstract

Hepatic steatosis seems a frequent histological alteration seen in chronic hepatitis C virus infected patients. There is still a lot to learn about the exact mechanism of effect of liver steatosis and its influence on the progression of liver diseases. Our study involved 96 chronic hepatitis C genotype 1 infected Hungarian patients who received pegylated interferon and ribavirin treatment for the first time. Degree of steatosis, viral and host factors influencing its development and its effect on the efficiency of antiviral treatment were determined. In 61 (64%) of patients the liver tissue showed varying degree of steatosis, which did not show relationship with level of alcohol consumption (p = 0.5792), diabetes mellitus (p = 0.5925) or body mass index (p = 0.9685) in type 1 chronic hepatitis C patients. Degree of steatosis and virus titer showed strong relationship (OR = 2.1). Significant relationship was also found between degree of hepatic steatosis and stage (p = 0.0119), as well as between therapeutic response to combined pegylated interferon + ribavirin treatment and steatosis (p = 0.0012). Our results demonstrated that steatosis has clinical significance in hepatitis C virus genotype 1 infected patients.

Seeff LB, Buskell-Bales Z, Wright EC, National Heart, Lung and Blood Institute Study Group et al (1991) Long-term mortality after transfusion-associated non-A,non-B hepatitis. N Engl J Med 327:1906–1911CrossRef

Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349(9055):825–832CrossRefPubMed

Mihm S, Fayyazi A, Hartmann H et al (1997) Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25:735–739CrossRefPubMed

Czaja AJ, Carpenter HA, Santrach PJ et al (1998) Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29:198–206CrossRefPubMed

Hourigan LF, Macdonald GA, Purdie D et al (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219CrossRefPubMed

Rubbia-Brandt L, Quadri R, Abid K et al (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotypes 3. J Hepatol 33:106–115CrossRefPubMed

Adinolfi LE, Gambardella M, Andreana A et al (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358–1364CrossRefPubMed

Serfaty L, Andreani T, Giral P et al (2001) Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428–434CrossRefPubMed

Monto A, Alonzo J, Watson JJ et al (2002) Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus, and alcohol. Hepatology 36:729–736CrossRefPubMed

10.

Westin J, Nordlinder H, Lagging M et al (2002) Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37:837–842CrossRefPubMed

11.

Hui JM, Kench J, Farrell GC et al (2002) Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17:873–881CrossRefPubMed

12.

Castéra L, Hézode C, Roudot-Thoraval F et al (2003) Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52:288–292CrossRefPubMed

13.

Poynard T, Ratziu V, McHutchinson J et al (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75–85CrossRefPubMed

14.

Asselah T, Boyer N, Guimont MC et al (2003) Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 52:1638–1643CrossRefPubMed

15.

Rubbia-Brandt L, Fabris P, Paganin S et al (2004) Steatosis affects chronic hepatitis C progression in a genotype-specific way. Gut 53:406–412CrossRefPubMed

16.

Patton HM, Patel K, Behling C et al (2004) The impact of steatosis on disease progression and early sustained treatment response in chronic hepatitis C patients. J Hepatol 40:484–490CrossRefPubMed

17.

Asselah T, Rubbia-Brandt L, Marcellin P et al (2006) Steatosis in chronic hepatitis C: why does it really matter? Gut 55:123–130CrossRefPubMed

18.

Allison ME, Wreghitt T, Palmer CR et al (1994) Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135–1139CrossRefPubMed

19.

Caronia S, Taylor K, Pagliaro L et al (1999) Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059–1063CrossRefPubMed

20.

Mason AL, Lau JY, Hoang N et al (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328–333CrossRefPubMed

21.

Petit JM, Bour JB, Galland-Jos C et al (2001) Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35:279–283CrossRefPubMed

22.

Mehta SH, Brancati FL, Strathdee SA et al (2003) Hepatitis C infection and incident type 2 diabetes. Hepatology 38:50–56CrossRefPubMed

23.

Hui KQ, Esrailian E, Runyon B et al (2002) Clinical implication of hepatic steatosis in patients with chronic hepatitis C. Hepatology 34:187A

24.

Kumar D, Farell GC, Fung C et al (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36:1266–1272CrossRefPubMed

25.

Moriya K, Yotsuyanagi H, Shintani Y et al (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527–1531PubMed

26.

Kumar D, Farrell GC, Fung C et al (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36:1266–1272CrossRefPubMed

27.

Gervain J, Simon G, Papp I et al (2001) Determination of the type and subtype of the hepatitis virus C in chronic viral hepatitis patients in Hungary. Orv Hetil 142:1315–1319PubMed

28.

Tornai I, Dalmi L, Gervain J et al (2005) Treatment of patients with chronic hepatitis C, using pegylated interferon alfa-2a and ribavirin — the first experiences in Hungary based upon a multicentric, open, prospective study. LAM 15:807–813

29.

Ishak K, Baptista A, Bianchi L et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699CrossRefPubMed

30.

Brunt EM, Janney CG, Di Bisceglie AM et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474CrossRefPubMed

31.

Jármay K, Karácsony G, Nagy A et al (2005) Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 11:6422–6428PubMed

32.

Abid K, Pazienza V, de Gottardi A et al (2005) An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 42:744–751CrossRefPubMed

33.

Barba G, Harper F, Harada T et al (1997) Hepatitis C core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Nat Acad Sci USA 94:1200–1205CrossRefPubMed

34.

Shi ST, Polyak SJ, Tu H et al (2002) Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 292:198–210CrossRefPubMed

35.

Perlemuter G, Sabile A, Letteron P et al (2002) Hepatitis C core protein inhibits microsomal triglycerid transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16:185–194CrossRefPubMed

36.

Fartoux L, Chazouilleres O, Wendum D et al (2005) Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41:82–87CrossRefPubMed

37.

Day CP, James OFW (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845CrossRefPubMed

38.

Lee KS, Buck M, Houglum K et al (1995) Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 96:2461–2468CrossRefPubMed

39.

Bedossa P, Houglum K, Trautwein C et al (1994) Stimulation of collagen alpha 1(1) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis? Hepatology 19:1262–1271PubMed

40.

Parola M, Pinzani M, Casini A et al (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (1) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044–1050CrossRefPubMed

41.

Farinati F, Cardin R, De Maria N et al (1995) Iron strorage, lipid peroxidation and glutathion turnover in chronic anti-HCV positive hepatitis. J Hepatol 22:449–456CrossRefPubMed

42.

Paradis V, Mathurin P, Kollinger M et al (1997) In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 50:401–406CrossRefPubMed

Title: Effect of Liver Steatosis on Therapeutic Response in Chronic Hepatitis C Virus Genotype 1 Infected Patients in Hungary
Authors: Klara Werling
Zsuzsa Schaff
Elek Dinya
Zsolt Tulassay
Publication date: 01-06-2010
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-009-9195-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Clinical Significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 Receptors in Pancreatic Ductal Adenocarcinoma

Extraosseus Plasmacytoma of the Pharynx with Localized Light Chain Deposition. Case Report

Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway

Reduced β-catenin Expression is Associated with Good Prognosis in Astrocytoma

Proximal-Type Epithelioid Sarcoma in the Groin Presenting as a Diagnostic Dilemma

Primitive Testicular Leiomyosarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer